Axsome Therapeutics Inc
NASDAQ:AXSM

Watchlist Manager
Axsome Therapeutics Inc Logo
Axsome Therapeutics Inc
NASDAQ:AXSM
Watchlist
Price: 177.27 USD 1.8% Market Closed
Market Cap: 8.9B USD

Net Margin

-40.9%
Current
Improving
by 68.2%
vs 3-y average of -109.1%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-40.9%
=
Net Income
$-229.6m
/
Revenue
$561.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-40.9%
=
Net Income
$-229.6m
/
Revenue
$561.3m

Peer Comparison

Country Company Market Cap Net
Margin
US
Axsome Therapeutics Inc
NASDAQ:AXSM
8.9B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
Loading...
CH
Roche Holding AG
SIX:ROG
276.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
215.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
221.7B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.7B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...
No Stocks Found

Market Distribution

Lower than 80% of companies in the United States of America
Percentile
20th
Based on 15 072 companies
20th percentile
-40.9%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Axsome Therapeutics Inc
Glance View

Axsome Therapeutics Inc. emerged as a dynamic player in the biopharmaceutical arena, driven by a resolute commitment to alleviate the burdensome effects of central nervous system (CNS) disorders. Founded with a vision to fill critical treatment gaps in neurologically influenced conditions, Axsome leverages innovative drug discovery and development to address medical needs that have long been underserved. The company focuses intently on conditions such as depression, migraine, narcolepsy, and Alzheimer's disease-related agitation, channeling resources into a streamlined pipeline that seeks to fast-track the development and commercialization of life-changing therapies. Operating at the intersection of cutting-edge science and patient-centric healthcare, Axsome generates revenue through the successful approval and marketing of its proprietary pharmaceutical products. The company's business model hinges on advancing its clinical candidates through rigorous trials, eventually gaining the necessary regulatory endorsements to bring them to market. By holding the intellectual property rights for these novel drugs, Axsome enjoys the advantages of exclusivity in the marketplace, which allows it to negotiate favorable pricing and reimbursement terms. This strategic approach not only positions Axsome as a potentially transformative force within the pharmaceutical industry but also underlines its commitment to producing viable, accessible treatments for those grappling with debilitating CNS disorders.

AXSM Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-40.9%
=
Net Income
$-229.6m
/
Revenue
$561.3m
What is Axsome Therapeutics Inc's current Net Margin?

The current Net Margin for Axsome Therapeutics Inc is -40.9%, which is above its 3-year median of -109.1%.

How has Net Margin changed over time?

Over the last 3 years, Axsome Therapeutics Inc’s Net Margin has increased from -622.8% to -40.9%. During this period, it reached a low of -622.8% on Sep 30, 2022 and a high of -40.9% on Sep 30, 2025.

Back to Top